){kind=logo}
From Promise to Performance: Scaling Emerging Therapies
As exosomes, peptides and next-generation therapies gain momentum, enterprise medspas must decide what belongs on the menu ' and what is ready to scale. Weigh consumer demand, evolving evidence, and the rewards of building repeatable protocols across locations, to strengthen patient trust, protect clinical credibility, and support sustainable growth.